苯磺酸瑞马唑仑与丙泊酚用于有创机械通气长期镇静的比较:一项先导研究
该单中心随机先导研究纳入机械通气超过24小时的成人患者,随机接受苯磺酸瑞马唑仑或丙泊酚镇静,目标RASS为-3至0。每组30例,两组无救援镇静且处于目标RASS范围的时间百分比中位数相似(瑞马唑仑组73.2% vs 丙泊酚组82.8%,p=0.269)。第7天无呼吸机天数、ICU住院时间、28天死亡率及不良事件均无差异。作者认为苯磺酸瑞马唑仑用于长期镇静有效且安全。
要点
- 机械通气>24 h成人患者中,苯磺酸瑞马唑仑组无救援镇静且目标RASS(-3至0)时间百分比中位数为73.2%(IQR 41.5-97.3%),丙泊酚组为82.8%(IQR 65.6-100%),p=0.269。
- 两组第7天无呼吸机天数、ICU住院时间、28天死亡率及不良事件均无差异。
- 两组中位年龄分别为60.0岁(IQR 51.5-66.3)与64.0岁(IQR 55.0-69.3),p=0.437;中位研究药物输注时长分别为55.0小时(IQR 28.3-102.0)与41.0小时(IQR 24.8-74.3),p=0.255。
- 作者认为,与丙泊酚相比,苯磺酸瑞马唑仑用于机械通气患者长期镇静有效且安全。
适用人群与场景
- 成人患者,机械通气时间超过24小时,接受长期镇静。
诊断标准与关键阈值
- 目标镇静范围为里士满躁动-镇静量表(RASS)-3至0分。
处置流程与药物剂量
- 随机接受苯磺酸瑞马唑仑(苯磺酸瑞马唑仑)或丙泊酚镇静,具体剂量、给药途径及调整方案原文未报告。
研究设计与关键结果
- 单中心随机先导研究,每组30例;主要终点为无救援镇静且处于目标RASS范围的时间百分比,瑞马唑仑组中位数73.2%(IQR 41.5-97.3%)vs 丙泊酚组82.8%(IQR 65.6-100%),p=0.269。
- 两组中位年龄60.0岁(IQR 51.5-66.3)vs 64.0岁(IQR 55.0-69.3),p=0.437;中位研究药物输注时长55.0小时(IQR 28.3-102.0)vs 41.0小时(IQR 24.8-74.3),p=0.255。
- 第7天无呼吸机天数、ICU住院时间、28天死亡率及不良事件两组间均无差异。
证据类型、等级与局限
- 证据类型:单中心随机先导研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与丙泊酚相比,苯磺酸瑞马唑仑用于机械通气患者长期镇静有效且安全。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of remimazolam besylate compared with propofol in maintaining mild-to-moderate sedation in patients receiving long-term mechanical ventilation.
METHODS: In this single-centered randomized pilot study, adult patients mechanically ventilated longer than 24 h were randomized to receive remimazolam besylate or propofol. The target sedation range was - 3 to 0 on the Richmond Agitation and Sedation Scale (RASS). The primary outcome was the percentage of time in the target sedation range without rescue sedation. The secondary outcomes were ventilator-free days at day 7, the length of ICU stay and 28-day mortality.
RESULTS: Thirty patients were assigned to each group. No difference was identified between the remimazolam group and propofol group in median age [60.0 (IQR, 51.5-66.3) years vs. 64.0 (IQR, 55.0-69.3) years, respectively, p = 0.437] or the median duration of study drug infusion [55.0 (IQR, 28.3-102.0) hours vs. 41.0 (IQR, 24.8-74.3) hours, respectively, p = 0.255]. The median percentage of time in the target RASS range without rescue sedation was similar in remimazolam and propofol groups [73.2% (IQR, 41.5-97.3%) vs. 82.8% (IQR, 65.6-100%), p = 0.269]. No differences were identified between the two groups in terms of ventilator-free days at day 7, length of ICU stay, 28-day mortality or adverse events.
CONCLUSIONS: This pilot study suggested that remimazolam besylate was effective and safe for long-term sedation in mechanically ventilated patients compared with propofol.
参考来源
- Tang Y, Yang X, Yu Y, et al. Remimazolam besylate versus propofol for long-term sedation during invasive mechanical ventilation: a pilot study. Crit Care. 2022. PMID: 36114552. doi:10.1186/s13054-022-04168-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。